New way of expanding cancer screening for minority women

October 25, 2010

New York, October 25, 2010 -- Minority patients have a significantly decreased survival from colon cancer compared to white patients, most often as a result of a late diagnosis. To help address this problem, a team of healthcare professionals at Memorial Sloan-Kettering Cancer Center has identified an efficient way to increase minority access to lifesaving colorectal cancer screening (CRCS) in communities where multiple barriers to preventive care exist. In the November 8 issue of the journal Cancer, the group reports how women living in Harlem were introduced to CRCS during their routine mammography screening.

"We hypothesized that mammography centers, similar to the one where this study took place, offer a unique opportunity to introduce the concept of colon cancer screening, because the women being tested are most likely already familiar with the concept of cancer screening," explained Moshe Shike, MD, an attending physician at Memorial Sloan-Kettering Cancer Center and the study's lead author. "Unfortunately, minorities in this community often have a late diagnosis and subsequent poor outcome from colon cancer because they are not able to - for one reason or another - access the routine preventive care they need. However, minority women, including many living in Harlem, are taking advantage of mammography screening as a result of ongoing outreach and education efforts."

In Harlem, Manhattan's northernmost community, the survival rate for colorectal cancer - the nation's second leading cause of cancer mortality - is low. Research has identified several contributing factors to the late diagnosis and lack of screening in this community, including little or no medical insurance, language barriers, distrust of the medical community at large, and under-representation in the healthcare system. But as health reform moves forward, and a stronger emphasis is placed on preventive care, communities around the country will need to find ways to facilitate the screening process, as well as find ways to fund it, notes Dr. Shike.

The teams' study took place at the Breast Examination Center of Harlem (BECH) -- a community outreach program of Memorial Sloan-Kettering that offers free, high-quality care, including cervical and breast cancer screening to primarily African-American and Hispanic women. Women aged 50 years or older who had not undergone colon cancer screening in the past ten years were eligible to participate. (Eligibility was also based on patients not having serious illnesses such as heart or lung disease or uncontrolled diabetes.) Following the patients' mammography, eligible women met with bilingual staff to learn about the screening process and ascertain whether they were eligible to undergo colonoscopy. This process, Dr. Shike pointed out, can be effective and reduce costs because women can be referred, medically screened, and prepared without having to obtain a referral from another physician.

"We rode the coattails of an already successful, preexisting screening program model and showed that by introducing colon cancer screening at this time, we were able to facilitate the process and expand access," explained Dr. Shike. "This is important because many women coming to facilities like BECH have little or no health insurance, and many do not see a primary care physician regularly. We were able to remove the burden of having to obtain a referral, which in many cases leads to patients not getting the screening they need."

Of 2,616 eligible women, 611 patients initially gave their consent. Although fewer than 25 percent of those eligible joined the study, the researchers point out that the lack of involvement was not for lack of interest. "Only a small percentage cited a lack of interest for declining screening," noted Dr. Shike. "Once the eligible patients were sitting face-to-face with a healthcare provider, the majority of women were engaged in the discussion."

"Our colonoscopy findings in this study are similar to those in the general population, so offering colon cancer screening to underserved, minority women at the time of mammography, without a doctor's referral, is an effective way to expand screening," said Dr. Shike, who notes that alternatives to traditional medical insurance continue to be a barrier to access for the uninsured.
-end-
This study was supported by the National Cancer Institute and the American Cancer Society.

Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. These specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to www.mskcc.org.

Memorial Sloan Kettering Cancer Center

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.